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Abstract
Background: CD25, a component of the IL-2 receptor, is important in T cell proliferation, activation induced cell death, as
well as the actions of both regulatory (Treg) and effector (Teff) T cells. Recent genome wide association studies have
implicated the CD25 locus as an important region for genetic susceptibility to a number of autoimmune disorders, with
serum levels of soluble CD25 receptor (sCD25) serving as a potential phenotypic marker for this association. However, the
functional impact of CD25 cleavage, as well as the influence of sCD25 on immunoregulatory activities, remain largely
unknown and form the basis of this effort.
Methodology/Principal Findings: The generation of sCD25 by Treg (CD4
+CD25
+) and Teff (CD4
+CD25
2) cells was examined
during in vitro suppression assays, efforts that demonstrated constitutive and stable surface CD25 expression on Treg
throughout the period of in vitro assessment. In contrast, Teff cells increased CD25 expression during the process of in vitro
suppression, with supernatant sCD25 levels correlating to the amount of cellular proliferation. Interestingly, under serum-
free conditions, Tregs partially lost their characteristic anergic and suppressive properties. sCD25 supplementation at
physiological concentrations to serum free in vitro suppression assays reduced Teff proliferation without specifically
influencing suppression. Indeed, sCD25 production within these cultures correlated with cell death.
Conclusions/Significance: These results support the notion that sCD25 functions as both a surrogate marker of T cell
activation as well as an indicator of subsequent cellular death. In addition, the role of CD25 in immunomodulation is likely
dependent on the local inflammatory milieu, with molecules capable of modulating surface CD25 expression playing a key
role in defining immune responsiveness.
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Introduction
Interleukin-2 (IL-2) has long been recognized for its role in
promoting T cell proliferation in vitro, yet only recently has
appreciation grown for its paradoxical role in maintaining
peripheral tolerance in vivo. One key means by which IL-2
appears to promote tolerance involves its influence over
CD4
+CD25
+ T cells, often termed regulatory T cells (Treg). In
1995, Sakaguchi and colleagues identified the a-chain of the IL-2
receptor (CD25) as a putative marker of functional Treg [1]. The
high-affinity, trimeric IL-2 receptor complex consists of three
major sub-units; the a-chain (designated CD25), the b-chain
(CD122), and the common cytokine receptor c-chain (CD132) [2].
These subunits, as well as other fragments of the molecule, appear
to play important roles not only in immune physiology, but as
markers of immune activity.
The concept that the expression level and affinity of cell surface
receptors dictates cellular fate was introduced as the quantal
theory by Kendall A Smith [3]. In activated T cells, signaling
through the IL-2 receptor results in increased high-affinity
receptor expression and eventual activation induced cell death
(AICD) through up-regulation of Fas and FasL [4,5]. It has been
known since 1985 that production of the soluble form of CD25
(sCD25) associates with T cell activation in vitro [6]. In healthy
individuals, sCD25 is present in serum at approximately 2 ng/ml,
whereas increased serum sCD25 levels have been associated with
lymphocyte activation in infection as well as in hematologic
malignancies [7,8]. More recently, polymorphisms in the CD25
gene have been associated with autoimmune diseases such as type
1 diabetes, multiple sclerosis, and Graves’ disease; with measurable
differences in serum levels of the soluble form of the corresponding
molecule (i.e., sCD25) [9–12]. These data point to, but do not
specifically identify, a functional role for sCD25 separate from its
value as a biomarker of activation in serum. Indeed, several key
questions regarding sCD25 remain unanswered. These include
those asking what biological actions result in the formation of
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immune responsiveness?
While an alternative splice variant cannot be ruled out as
contributing to the production of sCD25 [13,14], it is more
commonly thought that sCD25 results from a proteolytic cleavage
event driven by a family of enzymes collectively referred to as
‘‘sheddases’’. To date, at least three enzyme candidates have been
reported to possess the capacity for cleaving CD25 including the
endogenous enzymes elastase and matrix metalloproteinase-9
(MMP-9), as well as the environmental house dust mite allergen
DerP1 [15–17]. While these enzymes have each been shown to be
sufficient to elicit cleavage, the formation of sCD25 is often still
observed in their absence or in the presence of enzymatic
inhibitors. Thus, there may be additional unidentified-enzymes
or overlapping enzymes responsible for sCD25 formation.
It has been suggested that sCD25 itself may bind IL-2 in vivo,
preventing it from forming complexes with a2-macroglobulin and
thus preserving its bioavailability for T cells [18]. The affinity of
the monomeric soluble receptor for IL-2 is relatively low
(Kd=30 nM) [19]. This is comparable to the affinity of the
monomeric membrane a-chain for IL-2 (Kd=10
28 M), followed
by that of the intermediate bc complex (Kd=10
29 M) and finally
the high-affinity abc-trimeric complex (Kd=10
211 M) [20]. An
antagonistic role for sCD25 has also been suggested [21]. More
recent studies have depicted sCD25 as an early inhibitor of IL-2
signaling in T cells that also enhances their proliferation in short
and long term in vitro culture [12]. If this molecule is indeed
participating in IL-2 signaling as suggested, then it may be possible
to apply the quantal theory to this soluble receptor. sCD25 could
then be expected to play multiple roles depending on the local
environment in regards to IL-2 concentration, cellular activation
state, and the amount of sCD25 present.
Methods
Objectives
We hypothesized that the control of membrane and soluble
forms of CD25 on CD4
+ T cells is critical for regulating immunity
and tolerance, and that the presence of sCD25 and other factors in
serum may be influencing in vitro assays. Herein, we describe
efforts addressing these notions as well as our attempts to shed light
on the aforementioned knowledge voids regarding sCD25
production and function. We sought to investigate the production
of sCD25 during in vitro suppression assays as well as during
PBMC activation. In addition, we explored the role of sCD25
during suppression and proliferation via addition of recombinant
protein to in vitro assays for this activity. These efforts attempted to
avoid interference from sCD25 present in supplemented serum by
using serum free media. Taken together, we believe this effort
provides valuable insights into the role of CD25 stability and
sCD25 production on the process of immune regulation.
Participants
Peripheral blood was obtained from normal healthy control
subjects (11M/6F; median age 30.4, range 21.1 to 45.4 years)
without a recent infection, allergic episode, or having a known
autoimmune disorder.
Description of Procedures or Investigations undertaken
Staining and Flow Cytometry. Cells were aliquoted (0.5–
1610
6 in 100 ml per tube) along with each appropriate antibody,
including anti-CD3 (clone HIT3a), anti-CD25 (M-A251), anti-
CD4 (SK3), anti-CD127 (clone hIL-7R-M21), or isotype controls
mouse IgG1 (X40), mouse IgG1 (MOPC-21), and mouse IgG2b
[27–35] (BD Biosciences). FOXP3 staining was conducted with
the anti-human FOXP3 (clone 206D) staining kit according to
manufacturer recommendations (Biolegend). Flow cytometric
analysis was conducted using FCS Express (De Novo Software)
or FlowJo software (version 7.2.2, TreeStar).
Cell Purification and Fluorescence-Activated Cell
Sorting. Cells used in functional suppression assays were
separated into a T cell depleted accessory cell population
(irradiated 3300 rads) and functional CD4
+CD25
+ Treg and
CD4
+CD25
2 Teff cells. The untouched accessory cell population
was produced by incubating an aliquot of blood (5 ml) with a T
cell depletion antibody cocktail (RosetteSep; StemCell), followed
by density gradient centrifugation (Cellgro) with Ficoll-hypaque
solution (Amersham/GE Healthcare). CD4
+ T cells were pre-
purified from the remaining blood by negative selection using a
CD4
+ T cell enrichment cocktail (Stem Cell). Briefly, 50 mlo f
cocktail per 1 ml of whole blood was incubated for 20 min at
23uC, subjected to density gradient centrifugation, washed twice in
PBS (Ca
++ and Mg
++ free) containing 0.1% BSA (Sigma-Aldrich),
then this ‘‘untouched’’ CD4
+ population underwent an additional
high-speed FACS sorting procedure to yield CD4
+CD25
Hi Treg
cells and CD4
+CD25
2 Teff cells. For specified assays, the CD127
marker was also used during sorting to yield CD4
+CD127
2/
loCD25
+ T cells, as these cells have been reported to contain a
highly enriched FOXP3
+ population [22]. Sorted Treg and Tconv
cell populations were analyzed for purity following FACS with
anti-human FOXP3 (Figure S1). PBMC for later proliferation
experiments were isolated by density gradient centrifugation over
Ficoll-Hypaque.
Isolation of Purified Treg and Teff Cell Populations by
FACS. Pre-enriched CD4
+ T cells were stained by the addition
of anti-CD3 (clone HIT3a), anti-CD25 (M-A251), and anti-CD4
(SK3) antibodies at 5 ml/10
6 cells. PBS containing 2% human AB
serum was added for a final staining volume of 10
8 CD4
+ T cells/
ml (30 min at 4uC), washed in PBS/0.1% BSA wash buffer,
centrifuged (300 x g), and resuspended in wash buffer (3 ml) prior
to high-speed cell sorting on a BD FACSVantage Cell Sorter. Sort
gates for CD4
+CD25
Hi T cells were set to optimize the yield and
purity of FOXP3 expressing T cells within the CD4
+CD25
+ T cell
fraction [23]. Where indicated, anti-CD127 ((clone hIL-7R-M21),
BD Biosciences) was added to discriminate Treg from Teff cells.
Purified CD4
+CD25
HI and CD4
+CD25
2 T cell fractions were
collected in sterile tissue culture tubes (BD Biosciences) containing
cold (4uC) AIM V SFM (Invitrogen).
Cell Culture. Suppression assays were performed in AIM V
complete SFM (Invitrogen) with the addition of freshly isolated
autologous serum (heat inactivated at 56uC for 30 min), where
indicated. PBMC proliferation assays took place in either RPMI
1640 (CellGro) supplemented with 5% human AB serum (Cellgro),
or AIM V, XVIVO 15, or CTL Test serum free media. All assays
were performed in U-bottom 96-well plates (Costar) and
maintained at 37uCi n5 %C O 2.
Suppression Assay Co-culture System. CD4
+CD25
Hi Treg
cells were added in decreasing ratios (1:0, 1:1, K:1, and 0:1) to a
constant number of CD4
+CD25
2 Teff cells (5610
3 cells/well). A
combination of 5 mg/ml soluble anti-CD3 (clone HIT3a) and
2.5 mg/ml soluble anti-CD28 (clone CD28.2; eBioscience,)
provided proliferation stimulus for a 120 h culture period.
5610
4 irradiated (3300 rads) T cell depleted accessory cells were
also added to each well in a total volume of 200 ml. One mCi of
3H-Thymidine (Amersham Biosciences) was added at 96 h for a
final 16 h of culture to assess proliferation. Supernatants (20 ml/
well) from triplicate wells were collected at 48 h and 96 h to assess
sCD25 and cytokine production. Suppression was calculated by
CD25 Influence on Immunity
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3H-thymidine incorporation using the following
equation: Percent suppression = (1 - (mean CPM Treg+Teff)/
(mean CPM Teff) 6100%). For FACS based suppression assays,
proliferation was calculated by division index (DI), with
suppression calculated as previously described [24]. For T cell
subset proliferation assays, suppression assays were performed as
above but with co-cultures containing either normal or irradiated
Treg and Teff cell populations (3300 rads), or both.
Fluorescent Cell Labeling. To track proliferation of Treg
and Teff cells individually, each cell population was labeled with
either the ‘‘red’’ dye PKH26 (Sigma, final labeling concentration
2 mM) or ‘‘green’’ dye CFSE (Invitrogen, 1 mM), for Treg and Teff
cells, respectively [24]. For cell labeling experiments, functional
CD4
+CD127
lo/2CD25
+ Treg and CD4
+CD127
+ Teff cell popu-
lations were obtained by FACS. Suppression experiments were
conducted as described for
3H-thymidine based suppression
assays, in the following combinations (Treg to Teff cell ratios
1:0, 1:1, 1/2:1, 1/4:1, 1/8:1, 1/16:1, 1/32:1 and 0:1; where
1=5 610
4 cells). In addition, 5610
5 T cell depleted and irradiated
(3300 rads) accessory cells were added. Cultures were run in
triplicate and pooled prior to FACS analysis. At harvest, cells were
washed in PBS containing 0.2% BSA, stained with CD4-APC (BD
Biosciences), and analyzed by FACS for loss of cellular
fluorescence in both proliferating CD4
+ populations.
PBMC Proliferation Assays. Freshly isolated PBMC were
plated at 10
5 cells per well. Cells were left unstimulated or treated
with PHA-L (Sigma-Aldrich) at 5 ug/ml, or a-CD3 and a-CD28
coated beads (Miltenyi) at a bead:cell ratio of 1:2. In addition,
recombinant sCD25 was added at 2 and 20 ng/ml to duplicate
wells for each condition. One mCi of
3H-Thymidine (Amersham
Biosciences, Piscataway, NJ) was added at 96 h for a final 16 h of
culture to assess proliferation. Supernatants were collected at
96 hours to measure sCD25 and nuclear matrix protein 41/7.
Stimulation indices were determined by dividing the mean CPM
of stimulated cultures over relevant unstimulated controls.
Supernatant Cytokine, sCD25 and Nuclear Matrix Protein
Detection. Cytokines were assessed from cell culture supernatants
in a multiplex format utilizing the Luminex
100 xMAP System
(Austin, TX), with a multiplexed kit (BeadlyteH Human 22-plex
Multi-Cytokine Detection System 4; Upstate Biotechnology).
Samples were diluted 1:2 in AIM V medium prior to analysis.
sCD25 levels were determined byELISA according to manufacturer
instructions(BD Biosciences). Samples were diluted (when necessary)
in PBS containing 10% FBS (pH 7.0). To identify a normal range of
sCD25 in human serum, 60 samples were randomly selected from a
healthy control population of adolescents and adults, whose origins
were as previously described [23]. Soluble nuclear matrix protein
41/7 was measured by ELISA (Calbiochem, San Diego, CA)
according to manufacturer instructions.
Reagents. Recombinant sCD25 was obtained from R&D
Systems (Minneapolis, MN) for suppression assays, and from
Spring Biosciences for PBMC proliferation assays. Recombinant
MMP-2, MMP-9 and the selective MMP2/9 inhibitor were
acquired through Calbiochem (San Diego, CA).
Ethics
Institutional Review Board (IRB) approved informed consents
were obtained in accordance with approved protocols.
Statistical Methods
Statistical analyses utilized GraphPad Prism 4.00 software
(GraphPad, San Diego, CA), with Student’s paired t tests or
ANOVA with the Bonferroni post hoc correction for multiple
comparisons along with Spearman’s correlation analyses. For all
tests, p,0.05 was deemed significant.
Results
Treg Cells Require Serum for Optimal Suppression of T
Cell Proliferation
To investigate sCD25 production during the in vitro suppression
assay, peripheral blood CD4
+CD25
2 conventional T cells (Tconv)
and CD4
+CD25
Hi Treg were isolated by FACS. The isolated Treg
population demonstrated modestly lower CD4 expression and
CD25
Hi surface expression, which enriches for cells expressing
FOXP3 (Figure S1). To analyze the production of de novo sCD25
produced during the suppression assay from the levels already
present in healthy control human serum (2039.06899.8 pg/ml),
assays were conducted under serum-free media (SFM) conditions
or in SFM supplemented with specified concentrations of
autologous serum.
Surprisingly, serum absence markedly abrogated the ability of
Tregs to suppress proliferation as observed in
3H-thymidine-based
suppression assays (Figure 1A). This is in contrast to the standard
suppressive response; an assay whose outcomes could be fully
recovered by adding small (i.e., 1.0%) amounts of serum (Figure 1B).
Proliferation was significantly reduced in SFM compared to those
containing serum (Figure 1C). The reduced capacity of Treg to
suppress under serum free conditions could be a result of altered
cellular survival. To examine this possibility, we measured a marker
of cellular apoptosis and necrosis during the suppression assay in the
presence and absenceof serum.Nuclear matrix protein (NMP) levels
in culture supernatant were as follows in SFM: ((mean +/2 SEM)
1:0 Treg to Teff=57.7+/218.8, 1:1=279.3+/246, 0:1=254.3+/
235) and in 1% autologous serum: ((mean +/2 SEM) 1:0=39.6+/
210.7, 1:1=193.7+/216.9, 0:1=185.3+/251.5). Teff cell death
did not change in coculture with Treg, suggesting that the altered
suppression patterns observed in SFM were unlikely a result of
significant changes in cell death. Moreover, Tregs alone did not
exhibit significantly increased death in SFM alone. In fact, under
SFM conditions, Treg and Teff co-cultures often exhibited increased
proliferation over Teff cells alone (Figure 1D; % suppression at a 1:1
Treg to Teff ratio; mean + SEM, 2197.8+270.6 for SFM vs.
70.4+17.3 with 1.0% serum; p=0.04; Student’s paired T test). This
responsewasalsoobservedwhencellswereculturedataratioofK:1
Treg to Teff cells (2103.1691.5 vs. 34.8618.12, for SFM and 1.0%
serum, respectively; p=0.01).
The degree of in vitro suppression was dependent on both Treg
and Teff cell subsets. We noted a dramatically reduced
proliferation of Teff cells in SFM versus those in 1.0% serum
(Figure 1A and 1B, 0:1 condition; mean CPM =22,840+16,456
for SFM vs. 252,755+24,207 with 1.0% serum, p=0.0006),
whereas Treg proliferation was negligible irrespective of the
presence of serum when Treg were cultured alone.
Treg Cells Exhibit Reduced Suppressive Properties and
Proliferate when Cultured with Teff Cells under Serum
Free Medium Conditions
To assess the individual contributions of Treg and Teff to
proliferation in co-culture, these cells were FACS sorted
(Figure 2A) and then subjected to specific dyes (i.e., the red dye
PKH26 for Treg, green dye CFSE for Teff) (Figure 2B, left plot). In
vitro suppression assays were performed and proliferation tracked
by the loss of cellular fluorescence in each responding CD4
+ T cell
population (Figure 2B–2D).
In this system, CD4
+CD127
2/loCD25
+ T cells become anergic
in the presence of serum (Figure 2B, 1/4:1 Treg to Teff cell ratio;
CD25 Influence on Immunity
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overlaid histogram representing culture in 5.0% serum). Prolifer-
ation of PKH26 labeled Treg and CFSE labeled Teff cells were
tracked according to division index (DI) and plotted for all ratios of
Treg to Teff cells during the in vitro suppression assay (Figure 2C).
In an effort to more accurately measure the contribution of each
cell population to the increased proliferation, we also established a
suppression assay in SFM with either normal or irradiated Treg
and Teff cell populations (Figure 2E). This analysis indicated that
increased proliferation within the CD4
+CD25
+ T cell fraction is
predominantly responsible for the synergistic response observed in
the co-culture as similar proliferation levels were detected in the
presence of normal or irradiated Teff cells (33120.064866.0 vs.
28828.3361382.0 CPM, p=NS).
Production of sCD25 During Suppression Assay
TregandconventionalT cellshaveclassicallybeenselectedbased
upontheir expression of the membrane-bound form of CD25 under
baseline conditions [1]. In spite of this, little is known about what
happens to soluble and membrane CD25 during the in vitro
Figure 1. CD4
+CD25
+ Treg cells require serum for suppression of T cell proliferation. Suppression assays were conducted utilizing FACS
sorted cells run in parallel under either (A) SFM or (B) SFM supplemented with 1.0% autologous serum (n=7 healthy controls). Treg cells were plated
alone (5610
3 cells/well), and in decreasing ratios (1:1, K:1, and 0:1) to a constant number of Teff cells. Cells were stimulated with soluble anti-CD3
(5.0 mg/ml) and anti-CD28 (2.5 mg/ml) in the presence of a ten-fold excess (5610
4) of irradiated accessory cells. (C) Graph indicates data plotted from
panels (A) and (B) to highlight the differences in proliferation between serum free media (open bars) and 1% serum (closed bars). Cells proliferated
significantly less in SFM at Treg to Teff ratios of K:1 and 0:1 (p,0.001 for both conditions). (D). Graph indicates the percent suppression calculated
under serum-free conditions (open squares) and supplemented with 1.0% serum (closed squares) at a ratio of 1:1-Treg to Teff cells (left data points)
and at a ratio of K:1 Treg:Teff cells (right points). Under serum free conditions, Treg fail to suppress proliferation and often lead to increased
proliferation in the co-culture (% suppression = mean + SEM, 2197.8+270.6 for SFM vs. 70.4+17.3 with 1.0% serum; *p=0.04 at a ratio 1:1 Treg to
Teff. This trend continued at a ratio of K:1 Treg to Teff cell (2103.1+91.5 vs. 34.8+18.12, for SFM and 1.0% serum, respectively; **p=0.01). (*p,0.05,
**p,0.01, and ***p,0.001).
doi:10.1371/journal.pone.0007980.g001
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each condition during the suppression assay in order to determine
sCD25 production at 48 and 96 h time points (Figure 3). Overall,
this analysis indicated that Treg cells, which were selected based
upon high membrane CD25 expression levels, maintain CD25 in a
membrane-bound form following polyclonal activation in vitro
(Figure 3, 1:0 conditions). Teff cells, on the other hand, are known
to upregulate CD25 inresponseto activation, butthen subsequently
‘‘shed’’ it into the tissue culture medium (Figure 3D, 0:1 condition).
This type of analysis highlights the key influence of culture
conditions and timing on the production of sCD25. At an early
time point of 48 h, the highest levels of sCD25 are uniformly
observed in the 1:1 Treg to Teff cell co-culture under SFM and
serum supplemented conditions (Figure 3A,B). At a later time
point of 96 h, the detection of sCD25 more closely resembled the
proliferation data observed in the suppression assays (Figure 3C,D).
In this assay, the absence of serum resulted in detection of the
highest levels of sCD25 in the 1:1 Treg to Teff co-culture
condition (Figure 3C; mean + SEM, 3880.9+4756.5 pg/ml vs.
1043.3+863.8 for Teff cells alone). In line with the proliferation
results in the presence of serum, the highest levels of sCD25 were
also detected from Teff alone wells (Figure 3D, 0:1 condition;
5369.5+2575.6 pg/ml). A modest level of suppression in sCD25
levels was observed from the co-culture conditions at a ratio of 1:1
and 1/2:1 Treg to Teff cells (4311.1+2029.0 and 5245.3+2666.1,
respectively). Finally, in line with the anergic and suppressive
properties of Treg, the lowest levels of sCD25 were detected from
Treg cultures alone (Figure 3D, 682.2+367.1 pg/ml).
The Production of sCD25 Correlates with Cellular
Proliferation in the Suppression Assay
Considering the similar patterns of cellular proliferation and sCD25
production during the in vitro suppression assay, we sought to determine
the relationship between proliferation and sCD25 production. Under
both serum-free and serum-supplemented conditions, the production
of sCD25 at 96 hours correlated with the levels of cellular proliferation
Figure 2. Contribution of Treg and Teff cells to increased proliferation in suppression assay co-cultures. Peripheral blood CD4
+ T cells
((A), left plot) were FACS sorted based on surface expression of CD25 (y-axis) and CD127 (x-axis) to yield CD4
+CD127
lo/2CD25
+ T cells ((A), middle
plot) and CD4
+CD127
+CD25
2 Teff cells ((A), right plot). Following isolation, Teff cells were labeled with CFSE ((B), left plot, y-axis) and Treg cells
labeled with PKH26 ((B), left plot, x-axis). Proliferation of each gated CD4
+ T cell population was then assessed following activation conditions utilized
in the suppression assay. (B) Left plot indicates fluorescence levels of unstimulated cells (depicted in red for Treg and green for Teff), and following
96 h of in vitro activation ((B), right plots). Proliferation of Treg and Teff cells are shown at a J:1 Treg to Teff cell ratio and plotted under conditions of
SFM (dashed lines) or in the presence of 5% serum (solid lines). (C) For all ratios of Treg to Teff cells, Treg maintain increased suppressive potential
and anergic properties in the presence of serum as measured by division index (DI). (D) In vitro suppression calculated from DI indicated increased
suppression by Treg in the presence of serum. Data plotted represent one example of five independent experiments. (E) A standard suppression
assay was set up under SFM conditions with either standard or irradiated (3300 rads) Treg and Teff cells as indicated. This analysis demonstrated a
synergistic response at a 1:1 Treg to Teff ratio, with near maximal proliferation following addition of irradiated Teff cells. Statistical significance
indicated as *p,0.05, **p,0.01, and ***p,0.001.
doi:10.1371/journal.pone.0007980.g002
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r=0.67, p=0.0002 for SFM and r=0.76, p,0.0001 for 1.0% serum).
In order to determine the cellular source of sCD25, freshly
isolated CD4
+CD25
2 and CD4
+CD25
+ T cells were stimulated
individually in the presence of anti-CD3 and anti-CD28 coated
beads and exogenous IL-2. This analysis revealed that sCD25 can
be generated in an autocrine fashion from both Treg and Teff cells
following activation in the absence of any other cell types
(Figure 4). We found it intriguing that the culture conditions
which abrogate the anergic and suppressive properties of Treg
(i.e., by provision of cross-linking anti-CD3 and anti-CD28 co-
stimulation, as well as exogenous IL-2) represent the same
conditions that elicit the production of sCD25 from purified Treg.
It should once again be noted, however, that both proliferation
and sCD25 production were lower in Treg cells during expansion
cultures when compared to Teff cells (Figure 4C and 4D). This is
particularly apparent at the later time points of 96 and 120 h,
when Treg likely have consumed exogenous IL-2 (Figure 4D). We
would also note that production of sCD25 appears specific for the
growth factor present (herein IL-2), as production of sCD127 (the
IL-7R alpha-chain) was detected near background levels following
robust in vitro expansion (data not shown).
F i n a l l y ,g i v e nap r e v i o u sr e p o r ts u g g e s t i n gM M P - 2a n dM M P - 9
could elicit CD25 cleavage [15], we analyzed the capacity of these two
proteases to modify Treg and Teff cell responses. Consistent with that
report, we noted that addition of MMP-2 or MMP-9 in vitro reduced
Treg (Figure 5A, p,0.05 vs. vehicle) and to an even greater degree,
Teff cell proliferation under anti-CD3/anti-CD28 stimulation
(Figure 5B, p,0.05 vs. vehicle). Interestingly, addition of a selective
MMP-2/9 chemical inhibitor trended towards an increase in Teff
proliferation (Figure 5B, albeit p=NS), whereas Treg proliferation was
significantly reduced by addition of this inhibitor (Figure 5A, p,0.01).
Consistent with this notion, addition of the MMP-2/9 inhibitor to the
standard in vitro suppression assay increased the proliferative capacity of
Teff, while augmenting the suppressive function of Treg (Figure 5C).
Treg Maintain the Capacity to Suppress Teff Cell Cytokine
Production in Serum Free Media Conditions
In addition to suppressing proliferation, one of the hallmark
phenotypes of Treg is their capacity to suppress cytokine
Figure 3. Production of sCD25 during the in vitro suppression assay. Supernatants from triplicate wells were pooled and analyzed for the
production of sCD25 by ELISA (n=7 control subjects). Under conditions of both serum-free and 1.0% serum, the highest levels of sCD25 were
detected in the 1:1 Treg to Teff co-culture condition at the early 48 h time point, but were only significantly higher in media containing 1% serum ((A)
and (B)). At the 96 h time point ((C) and (D)), the pattern of sCD25 production more closely resemble the responses observed in the proliferation
assay assessed by uptake of
3H-thymidine. (*p,0.05, **p,0.01, and ***p,0.001).
doi:10.1371/journal.pone.0007980.g003
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suppression of proliferation by Treg in SFM conditions, we
questioned whether Treg were also deficient in their capacity to
suppress cytokine production by Teff cells. To test this notion,
supernatants were collected and analyzed for the production of a
panel of 22 cytokines by multiplex analysis (complete cytokine
results are contained in Table S1).
Surprisingly, Treg maintained their capacity to suppress Teff
cell cytokine production under both SFM and serum supplement-
ed conditions for a majority of cytokines analyzed. However, some
cytokines did exhibit increased production in co-culture under
SFM conditions, paralleling the proliferation results. In this case, it
is of interest to note that these responses tended to include
cytokines classically associated with a TR1o rT H2-associated
phenotype (e.g., IL-10 and IL-5). It is also worth noting that
despite the highest levels of proliferation in the Treg and Teff co-
culture condition (1:1 in SFM), the highest levels of IL-2 were still
detected from Teff cells alone (mean 6 SEM, 11.7610.2 pg/ml
for the 1:1 Treg to Teff cell condition vs. 129.6+155.5 for Teff
only). On the other hand, despite dramatically higher Teff cell
proliferation in the presence of serum (Figure 1C, 0:1 conditions),
little detectable IL-2 was observed at the 96 h time point in
supernatants.
Exogenous sCD25 Does Not Affect Suppression, but
Alters Proliferation of Teff Cells
We sought to determine the effect of sCD25 supplemented at
‘‘serum’’ concentrations on Treg function in the suppression assay
(Figure 6A). The addition of sCD25 did not affect suppression, but
did result in decreased proliferation in Teff cells alone (0 ng/
ml=586562410 CPM vs. 2 ng/ml=16566143.9, p=NS). These
results conflicted with what has been reported in the literature
[12].
Exogenous sCD25 has Variable Effects on PBMC
Proliferation and is Dependent on the Culture Milieu
Our previous data reflecting the influence of serum presence
along with the trend seen in (Figure 6A) led us to investigate the
effects of multiple culture conditions and stimuli on production
Figure 4. Levels of cellular proliferation correlate with the production of sCD25. Levels of sCD25 produced during the in vitro suppression
assay were plotted versus the amount of proliferation detected at the 96 h time point. Under both (A) SFM and (B) 1.0% serum conditions, for all
ratios of Treg to Teff cells (1:0, 1:1, K:1, and 0:1, n=7), the levels of sCD25 detected (x-axis) correlate with cellular proliferation as assessed by the
incorporation of
3H-Thymidine (y-axis). Isolated Treg and Teff cells were then assessed for their capacity to proliferate and produce sCD25 in an
autocrine fashion over a 5 day time period. Purified CD4
+CD25
+ (open bars) and CD4
+CD25
2 T cells (closed bars) were cultured under expansion
conditions utilizing beads coated with anti-CD3 and anti-CD28 as well as exogenous human recombinant IL-2 (300 U/ml) under serum-free
conditions. Shown are (C) proliferation and (D) sCD25 production at 48, 72, 96, and 120 h time points by each indicated cell population. The data
plotted represent the mean CPM and pooled sCD25 levels of replicate cultures (n=6 individuals) with situations identifying significance between
Treg and Teff cells indicated (*p,0.05, **p,0.01, and ***p,0.001).
doi:10.1371/journal.pone.0007980.g004
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rather than isolated effects, we used total PBMC (n=10) and
direct TCR stimulus (anti-CD3 and anti-CD28 coated beads) as
well as a mitogenic T cell stimulus (PHA-L). We chose four media
formulations to compare the results between these assays -
standard conditions with RPMI 1640 with 5% human AB serum,
as well as three different serum free media - AIMV, XVIVO, and
CTL Test media. sCD25 was added at 0, 2, and 20 ng/ml to
approximate the levels present in serum and those that may persist
at areas of inflammation. With direct TCR stimulus (Figure 6B,
hatched bars), the high dose of sCD25 significantly increased
proliferation as compared to the control by ANOVA in RPMI
(0 ng/ml=70.8566.894 vs. 20 ng/ml=112.266.55, p,0.05),
AIMV (0 ng/ml=144.768.695 vs. 20 ng/ml=206.6619.33,
p,0.001) and XVIVO media (0 ng/ml=114.466.453 vs.
20 ng/ml=174.4616.33, p,0.01). Under mitogenic stimulus
(Fig. 6B, open bars), only cultures in XVIVO medium exhibited
increased proliferation (0 ng/ml=164.1613.39 vs. 20 ng/
ml=231.8626.55, p,0.001) while showing a decreasing trend
in CTL serum free medium (Figure 6B). These comparisons
indicate that substrate as well as matrix constituents in media lead
to significantly different proliferation.
Exogenous sCD25 May Increase Survival in PBMC
Cultures
To determine if this proliferation difference was due to
differential cell death in these cultures, nuclear matrix protein
41/7 (NMP 41/7) was measured in supernatant by ELISA
(Figure 6C). Increasing concentrations of sCD25 alone had no
affect on cell death by ANOVA (p=NS for all comparisons).
Comparisons following stimulation in the various culture medium
revealed that cell death could be altered by both factors: stimulus
(AIMV: 0 ng/ml=738.1647.9 (with PHA) vs. 301.1649.33 (3/
28), p,0.01; 2 ng/ml=832.26151.8 (PHA) vs. 313.6642.36 (3/
28), p,0.01; 20 ng/ml=824.96136.7 (PHA) vs. 329653.41 (3/
28); ANOVA) and media formulation only with mitogenic
stimulus (PHA) (AIMV=798.4630.24 vs. RPMI=315.268.172
and vs. XVIVO=378.2611.64, both p,0.05; ANOVA). The
stimulation index correlated with cell death only with CD3/28
stimulation (Figure 6D, r=20.3371, p=0.0334). Interestingly, in
comparisons between media formulations, there were both positive
and negative correlations that were statistically significant. Cells
cultured in AIMV and XVIVO media showed decreased
proliferation with increased cell death, whereas PHA stimulation
in CTL medium resulted in increased proliferation with increased
Figure 5. Alteration of MMP-2 and MMP-9 activity alters Treg and Teff cell proliferation and in vitro suppression. FACS isolated Treg
(A) and Teff (B) were activated with anti-CD3 and anti-CD28 coated microbeads in the presence of vehicle control or the selective MMP-2/9 chemical
inhibitor II (IC50=250 nM). Addition of active recombinant MMP-2 and MMP-9 (1 mg/ml each) led to reduced proliferation of Treg (A) and significantly
reduced proliferation of Teff (B) cells. The inhibitor reduced proliferation of Tregs (p,0.01) while having no effect on Teffs. (C) The addition of MMP-2/
9 inhibitor to the in vitro suppression assay resulted in increased Teff proliferation while at the same time, augmenting Treg-mediated suppression.
Percent (%) suppression at 1:1 (Treg/Teff) and K:1 ratios are noted above the bars, as a comparison to vehicle (0:1) or MMP-2/9 inhibitor (0:1) CPM.
Graphs show one representative experiment of three individual experiments. (*p,0.05, **p,0.01, and ***p,0.001).
doi:10.1371/journal.pone.0007980.g005
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concentrations in local microenvironments may protect T cells
from AICD, thus allowing increased viability and proliferation.
Production of sCD25 by PBMC Correlates with Cell Death
The differing proliferation results in PBMC cultures as
compared to isolated T cell cultures led us to investigate the
production of sCD25 as a function of PBMC proliferation
(Figure 7). sCD25 levels measured in cultures with no exogenous
sCD25 (Figure 7A) varied in response to different stimuli in both
RPMI and AIMV medium (RPMI: PHA=1895262872 vs. 3/
28=74576916.8, p,0.001; AIMV: PHA=2148262114 vs. 3/
28=109576893.8, p,0.001). Comparison to proliferation
showed that the correlation seen earlier was absent in PBMC
(Figure 7B, p=NS by linear regression and Spearman correlation).
Instead, production of sCD25 correlated with cell death
(Figure 7C, PHA: r=0.7182, p,0.001, CD3/28: r=0.3882,
p=0.0133).
Discussion
In this report, we describe a critical facet influencing T
lymphocyte function; that being the differential control of
membrane and soluble forms of CD25 on T cell subsets. We
observed that CD25, which has commonly been used to select
functional Treg, remains stable on the surface of anergic and
Figure 6. Addition of soluble CD25 differentially effects proliferation of Teff cells and PBMC. A suppression assay was set up under
serum-free media ((A), open bars), or in the presence of a human recombinant sCD25 protein ((A), closed bars). Addition of sCD25 did not significantly
restore Teff cell responses or the anergic properties of Treg in serum-free conditions (p=NS for all Treg to Teff cell ratios, 1:0, 1:1, K:1, and 0:1). In the
0:1 condition, sCD25 did appear to reduce proliferation. sCD25 was added to PBMC cultures (n=10) in the presence of increasing concentrations of
sCD25, with anti-CD3/28 microbeads ((B), open bars) or PHA ((B), hatched bars) stimulation. Proliferation increased in some culture conditions and
decreased in others. Statistically significant increases were seen by ANOVA under 3/28 stimulation in RPMI (p=0.05), AIMV (p=0.001), and XVIVO
(p=0.001) media, and under PHA stimulation in XVIVO medium (p=0.01) when comparing 0 and 20 ng of sCD25 added. Comparisons among the
same stimulation showed that cells cultured in RPMI and AIMV media had significant differences in proliferation regardless of the amount of sCD25
added, with both PHA and CD3/28 stimulation. Under PHA stimulation, CTL cultures proliferated less than either XVIVO or AIMV cultures. To
determine if this differential proliferation was due to altered cell death, we measured the amount of nuclear matrix proteins (NMPs) released into the
supernatant by dying cells (C). Addition of sCD25 did not result in a dose-responsive increase in cell death. The outcome varied depending on the
culture media and stimulus. Plotting the stimulation index versus the production of NMP showed a negative correlation between proliferation and
cell death under CD3/28 stimulation ((D), bottom panel). *p,0.05, **p,0.01, and ***p,0.001.
doi:10.1371/journal.pone.0007980.g006
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hand, CD25 is upregulated on recently activated Teff cells, but is
then subsequently released into the culture medium. These
findings imply that Treg may obtain quantitatively and qualita-
tively greater levels of IL-2 signaling compared to Teff cells as a
result of increased membrane CD25 stability and affinity for IL-2.
These data also suggest that IL-2 production by Teff cells is
required to drive continued cell cycle progression and sCD25
production by both cell populations.
In an effort to isolate the production of sCD25 from the levels
added through serum supplementation, we conducted these
experiments in a complete SFM formulation. To our surprise,
the absence of serum impaired the in vitro suppression of
proliferation assessed by standard
3H-thymidine-based assays but
not Teff cell cytokine production. In terms of developing an
explanation for this phenomenon, we proposed three non-
mutually exclusive explanations. First, Tregs may be more
sensitive to a lack of serum components during co-culture. Second,
Tregs may be contaminated with non-regulatory T cell popula-
tions that are relatively serum independent. Third, Tregs lose their
anergic and suppressive properties under serum free conditions. In
testing these three potential explanations we noted that the degree
of in vitro suppression simultaneously takes into account the
responses of Treg and Teff cells. Here, we observed functional
deficiencies in both populations under SFM conditions, with a
marked hyporesponsiveness of Teff cells and a concomitant failure
by Treg to remain anergic and suppress proliferation. Despite
deficient responses of both populations during in vitro suppression,
cell tracking dye studies and markers of apoptosis/necrosis did not
indicate significant differences in cell death due to the absence of
serum. The addition of increased sorting stringency by inclusion of
CD127 did restore some of the suppressive capacity of Tregs
under serum free conditions, implying some contribution by non-
Tregs when only CD4 and CD25 were used to sort. However, cell
dilution dye assays tracking proliferation of Tregs and Teff cells
during suppression indicated increased cell cycling from the entire
population of Tregs in SFM making outgrowth of a small subset
during the culture an unlikely explanation for the increased
proliferation observed. In sum, the in vitro suppression assay is
highly sensitive to potential artifacts due to media components
when assessing proliferation alone and may provide only limited
insight into the potential in vivo function of Tregs.
In terms of which component(s) within serum are required for
full T cell activation as well as suppression by Treg, several
candidates are the focus of our ongoing investigations. One such
candidate, TGF-b, serves a wide variety of pleiotropic functions,
with a role for TGF-b in immune regulation forming the subject of
much recent debate. TGF-b is a major cytokine product of Treg
Figure 7. sCD25 production in the absence of exogenous recombinant protein correlates with cell death, not proliferation, of
PBMC. To determine if the variable results seen previously were present in other areas, we measured the production of sCD25 in the 0 ng/ml
condition with anti-CD3/28 microbeads ((A), open bars) or PHA ((A), hatched bars) stimulation. sCD25 production varied dependent on the stimulus
provided in RPMI and AIMV media conditions (RPMI: (PHA) 1895262872, (3/28) 74576916.8, p,0.001; AIMV: 2148262114, (3/28) 109576893.8,
p,0.001), but did not significantly differ between media formulations. In (B), sCD25 production did not correlate with proliferation as seen previously.
Rather, sCD25 was generated at levels correlating with cell death as measured by NMP production, (C) (PHA: r=0.7182, p,0.001, CD3/28: r=0.3882,
p=0.0133). ***p,0.001.
doi:10.1371/journal.pone.0007980.g007
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of these cells [26]. Furthermore, TGF-b can elicit the conversion
of CD4
+CD25
2 T cells into FOXP3
+ T cells [27]. The function of
Treg has been reported to be influenced by both the presence and
activation state of TGF-b (i.e., in serum, TGF-b often exists in an
inactive latent form (TGF-LAP)). In a related concept, the balance
of serum proteases and protease inhibitors represent additional
components which may serve dual roles by influencing the
cleavage of CD25, as well as through their capacity to modify the
activation state of TGF-b [15,28]. To the existing proteases
reported to cleave CD25 [15,16], here we add our findings that
addition of MMP-9 or MMP-2 has effects on both Treg and
Tconv cell responses. In addition, our data suggest that chemical
inhibition of specific proteases may also influence CD25 stability
and immune responsiveness. Controlling the proteolytic release of
CD25 from the surface of Treg or Teff cells may provide novel
therapeutic targets to alter IL-2 receptor signaling.
These findings raise the intriguing question of why CD25
appears to be more stable on the surface of Treg compared to Teff
cells following stimulation and how this observation influences the
downstream function of these cells. The IL-2 signaling axis can
elicit proliferation of T cells, but also contains at least two
mechanisms for controlling T cell expansion in response to
antigen. IL-2/CD25 interactions reinforce the metabolic fitness of
Treg, leading to dominant immune suppression [29]. In Teff cells,
excess IL-2 signaling can lead to AICD. We would speculate that
the CD25 shedding from freshly activated Teff cells observed in
these studies may be necessary to prevent these processes, allowing
for continued cycling as well as maintaining activation require-
ments in daughter cell populations.
If a stable IL-2 signal reinforces FOXP3 expression and Treg
function, one might expect situations that interrupt IL-2 signaling
to interfere with Treg activity. An example of this situation was
reported by Tang and colleagues who observed that intra-islet
Treg cells expressed reduced amounts of CD25 and Bcl-2, which
led to a functional imbalance of Treg and Teff cell populations
leading to the development of type 1 diabetes in non-obese
diabetic mice [30]. In addition, multiple reports in inflammatory
autoimmune diseases and studies of human T-cell leukemia virus
type-I (HTLV-1) associated lymphoma report elevated serum
levels of sCD25 and defective suppression by Treg [31–33].
Therefore, it appears consistent through multiple disease processes
that disturbances in the IL-2 and CD25 signaling axis are often
paralleled by defective immunoregulation by Treg. Some of the
factors which may influence CD25 stability, and subsequent
immune reactivity, are modeled in Figure S2.
As mentioned previously, at least two major hypotheses on the
formation of sCD25 exist. Either Treg express a membrane-stable
form of CD25, or Treg cultures fail to elicit the factors that lead to
the proteolytic cleavage of CD25. Tregs are capable of producing
sCD25 upon activation and IL-2 exposure suggesting that
production of IL-2 by Teff cells may account for their continued
sCD25 production and proliferation. These observations taken
during the in vitro suppression assay appear to indicate that not
only are adaptive cytokine levels important for T cell proliferation
and function but in addition, the stability of cytokine receptors
warrants further consideration.
The influence of serum seen in suppression assays indicated that
a more thorough investigation of culture conditions was required
to accurately compare inter-laboratory data. Therefore, PBMC
responses were measured under TCR or mitogenic stimulation
under various culture conditions. What we have described is that
the presence or absence of serum as well as the components of the
culture media influenced the data collected in terms of sCD25
production, proliferation and cell death. Overall, the addition of
exogenous sCD25 increased proliferation in three out of four
culture conditions. The results of these assays are difficult to
interpret, in that slight modifications in the in vitro environment
have an effect on multiple outcome measures. This may provide
an explanation for the variation between laboratory results, but
likely does not complete the story. Indeed, the presence of sCD25
appears to have differential effects on pre-activated naive T cells
versus whole PBMC.
These studies highlight the importance of the soluble and
membrane associated forms of CD25 in terms of influencing cell
proliferation, survival, and suppression via Treg. The extensive
variability between investigations as well as various culture
conditions highlights the need for increased standardization during
in vitro assays. This is also contingent upon a more complete
understanding of the in vivo microenvironments controlling immune
responses. In terms of future implications, these studies highlight
important facets to consider in diseases associated with abnormal
levels of sCD25 as well as defective regulation by Treg.
Limitations
The role of sCD25 remains obscure because of the variations in
culture conditions, and ultimately will have to be resolved in vivo by
knock-in of only the soluble form into mice. The observation that
sCD25 may promote survival is an intriguing possibility, one that
might have a basis in the stoichiometric competition for other
receptor subunits in the common gamma chain cytokine family,
where cleaved CD25 allows for a more homeostatic cytokine (i.e.,
IL-7, IL-15) signaling. We would argue that the relatively
abundant amount of sCD25 in serum would not simply be waste
and this is the subject of ongoing investigation.
What we can infer from these experiments though is that sCD25
production on the whole is more likely associated with activation
induced cell death than proliferation per se. In light of this, the
multipleproteaseslinked with apoptoticcelldeathmaybe involved in
releasing CD25 from the cell surface. Chief among these candidates
are caspases, which we assume would have access to CD25 upon
internalization of the IL-2 receptor. This is particularly pertinent
considering recent studies linking disease-associated polymorphisms
in CD25 with increased susceptibility to type 1 diabetes and multiple
s c l e r o s i s[ 9 , 1 1 ] .I nt h ec a s eo ft y p e1d i a b e t e s ,w er e p o r t e ds u s c e p t i b l e
alleles in type 1 diabetes were linked with lower serum levels of
sCD25 [9]. In addition, in the non-obese mouse model of type 1
diabetes, allelic variation of IL-2 was associated with reduced IL-2
expression correlating with impaired Treg activity [34]. Thus, defects
within the IL-2/CD25 signaling axis may constitute a conserved
immune/AICD defect predisposing to autoimmunity.
This study also draws attention to the necessity for standard-
ization of in vitro assays to allow for proper interpretation and
comparison of results. Proprietary media formulations in combi-
nation with batch and vendor variation in serum supplements
hamper in vitro comparisons. A recent publication regarding
difficulties in in vitro polarization of Th17 cells due to media
composition shows a problem that is understood but not fully
explored – that immune cell activity in vivo is highly dependent on
the location [35]. Thus, it may be necessary to define in vitro
conditions that are more truly reflective of the many environments
where immune cells perform their functions.
Supporting Information
Table S1
Found at: doi:10.1371/journal.pone.0007980.s001 (0.07 MB
PDF)
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PLoS ONE | www.plosone.org 11 November 2009 | Volume 4 | Issue 11 | e7980Figure S1 Isolation of Treg and T conventional cells from
human peripheral blood by FACS. Representative plots showing
(A) pre-sort expression profiles of CD4 (x-axis) and CD25 (y-axis,
left plots) or CD25 (y-axis) and CD127 (x-axis, middle plots)
following CD4 negative selection. Plots represent post-sort purity
of sorted cells indicating expression of CD4, CD25, CD127, and
FOXP3 for (B) T conventional cells and (C) Tregs. Post-sort
FOXP3 analysis was assessed immediately following FACS
isolation (right plots, black overlays represent isotype control and
blue overlays indicate FOXP3 staining, respectively).
Found at: doi:10.1371/journal.pone.0007980.s002 (0.77 MB TIF)
Figure S2 Membrane CD25 stability influences immune
responsiveness. A hypothetical model is shown depicting how
alterations in membrane-bound and soluble forms of CD25
(sCD25) may influence the activities of Treg and conventional T
(Tconv) cell subsets. The immunological microenvironment
provides costimulatory and cytokine signals through APC which
influence CD25 stability on Treg and Tconv cells. Both intrinsic
signals, through TCR signal strength and costimulation, as well as
extrinsic inflammatory signals such as TOLL ligand induced
proinflammatory cytokines may skew T cell phenotypes through
the production of proteases and subsequent cleavage of mem-
brane-bound CD25. Loss of membrane CD25 and IL-2 signaling
in Treg would result in reduced phosphorylation of STAT5 and
downstream FOXP3 expression. Conversely, in Tconv cell
populations IL-2 signal strength along with costimulatory and
cytokine differentiation signals would influence the lineage fate of
responding T cell populations. Loss of CD25/IL-2 high affinity
signaling from Teff cell populations would result in lower IL-2
affinity and/or dependence on signaling from other common c-
chain receptors for survival (such as IL-7, IL-15, and IL-21).
Conversely, Tconv cells activated under tolerogenic conditions
would lead to increased CD25 membrane stability and subsequent
FOXP3 expression attenuating effector responses (Th17, Th1, and
Th2) and reinforcing an induced Treg (iTreg) phenotype. The
signal strength as measured by both affinity and avidity for IL-2
(related to the alpha beta gamma combinations) is important in
driving proliferation but also AICD.
Found at: doi:10.1371/journal.pone.0007980.s003 (0.53 MB TIF)
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